Online inquiry

IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4707MR)

This product GTTS-WQ4707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6103MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ5123MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ1308MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ7767MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ2086MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ11062MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ6450MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ8313MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW